Starting early in 2020, Covid-19 put an unusually bright spotlight on the healthcare sector. Nearly three years later, while Covid hasn’t completely disappeared, the crisis has eased (opens in new tab).
The future of healthcare post-Covid is a discussion taking place in boardrooms and households across the country. Professional investors are evaluating the healthcare trends developing post-Covid that can make money for their clients. Do-it-yourself (DIY) investors are wise to do the same.
If there is a sector that belongs in every DIY investor’s portfolio, healthcare would be it. Between the favorable demographics of an aging population (opens in new tab) to the generally stable earnings growth of healthcare companies, healthcare stocks should deliver healthy returns over the long haul.
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
So, as we move out of the pandemic (opens in new tab) phase of Covid into an endemic situation where life goes on despite ongoing cases of the virus, trends are developing for a post-Covid world.
Here are three DIY investors that can ride to long-term profits.
Innovation Will Be a Big Theme
The process for developing the Covid vaccines was faster than any before. However, that doesn’t mean healthcare professionals are sitting around patting themselves on the back. On the contrary, they know innovation must keep pushing to the limits to ensure people are kept safe from future viruses.
“We can do this more quickly if we are well prepared,” Florian Krammer, Ph.D., a professor of vaccinology at the Icahn School of Medicine at Mount Sinai in New York, told Association of American Medical Colleges contributor Patrick Boyle in July.
“For influenza virus, we get variants each year. And because there are already influenza virus vaccines with an established safety record and a known correlate of protection [measurable signs that a person is immune], we can just make a strain change to update the vaccine — without the need for lengthy clinical development.”
Innovation is a theme that professional investors are watching with great interest. Covid revealed the strengths and weaknesses of the U.S. healthcare system. Innovation is needed to repair the cracks in the system.
Chris Shott, a healthcare analyst with J.P. Morgan, sees a host of innovation happening in the sector, specifically in biotech. The analyst recently said good things about Horizon Therapeutics (HZNP (opens in new tab)).
“[W]e like Horizon Therapeutics, which had one of the best product launches in that category with a drug called Tepezza for treatment of thyroid eye disease,” Shott told Barron’s in September.
In two years, Tepezza went from zero sales to $2 billion. Shott believes it could grow annual revenues to as much as $4 billion.
Demand for Home-Based and Virtual Care to Increase
A McKinsey & Company article from July suggested a shift from more expensive healthcare sites such as acute and post-acute facilities to less expensive home-based services and virtual care.
“We estimate that hospitals’ share of overall provider revenue could decline from about 47 percent in 2019 to about 44 percent by 2025, while the share of home and ambulatory sites will increase by one to two percentage points each over the same period,” stated the July 19 article.
UnitedHealth Group (UNH (opens in new tab)) is using home- and community-based care to deliver more value for the patients it serves. The company’s Optum HouseCalls program is one such initiative.
HouseCalls is an annual in-home clinical assessment (opens in new tab) that provides a complete picture of a patient’s overall health. This helps health plans manage care while reducing reimbursement issues. In addition, the service helps reduce overall healthcare spending.
UnitedHealth’s most significant move into home healthcare will happen when and if it completes its acquisition of LHC Group for $5 billion (opens in new tab).
Either way, home-based care will only grow in the years ahead.
Healthtech Continues to Change Sector
Healthcare technology is one area of the sector that’s expected to continue gaining traction post-Covid. McKinsey & Co. estimates that the healthcare services and technology segment are expected to grow by 8.2% annually from $50 billion in 2021 to $70 billion in 2025.
One company that continues to use technology to transform its business is Becton Dickenson (BDX (opens in new tab)). Known for providing medical supplies to hospitals and other healthcare facilities, it generates about 50% of its revenue from technology solutions, making it one of the largest medical technology companies worldwide.
Wellington Management portfolio manager Ann Gallo owns BDX stock.
“Becton Dickinson trades for a lower valuation. Its business is half medical supplies and half life-sciences tools and technologies,” Gallo told Barron’s. “It offers both an attractive value proposition and a nice growth outlook."
-
-
Longevity: The Retirement Problem No One Is Discussing
Many people saving for retirement fail to take into account how living longer will affect how much they’ll need once they stop working. What should they do?
-
Capital Gains Taxes Trap: How to Avoid Mutual Fund Tax Bombs
It’s bad enough when your mutual fund’s assets lose value, but owing unexpected capital gains taxes after those losses is doubly frustrating.
-
7 Best Energy Stocks to Buy Now
These top-rated energy stocks could see tailwinds from spiking oil and gas prices.
-
Stock Market Today: S&P 500, Nasdaq Close Lower for a Second Straight Day
Today's economic data included updates on home prices and consumer confidence.
-
The 5 Best Blue Chip Dividend Stocks to Buy Now
Dow stocks This mini-portfolio of blue chip dividend stocks is well-positioned to generate income and deliver outperformance in tempestuous market times.
-
How to Invest for a Recession
investing During a recession, dividends are especially important because they give you a cushion even if the stock price falls.
-
5 Chinese Stocks Still Worth a 'Ni Hao'
stocks to buy Chinese stocks, especially in technology and tech-esque industries, have a track's worth of hurdles ahead. But nimble investors might be able to turn a few of these shares into profits.
-
11 Emerging Market Stocks That Analysts Love
stocks It's been a rough stretch for the global equities market, but Wall Street's pros think these emerging market stocks are top plays going forward.
-
5 Hotel Stocks to Buy for a Summer Travel Boom
stocks COVID-19 cases are well off their highs, and vacation demand is ramping up. Here are five top-rated hotel stocks that could benefit.
-
140 Companies That Have Pulled Out of Russia
stocks The list of private businesses announcing partial or full halts to operations in Russia is ballooning, increasing economic pressure on the country.
